Shenguan Appoints Medical Expert Dr. Bin-Bing Zhou
Shenguan Holdings (Group) Limited has appointed Dr. Bin-Bing Zhou as its technological consultant.
Dr. Bin-Bing Zhou was recruited as an expert under the Thousand Talents Program (the eighth batch) of the Organization Department of the Communist Part of China’s Central Committee and that at the Shanghai municipal level (the second batch). He is currently the Head of the Institute of Translational Research in Pediatrics of the Shanghai Jiao Tong University’s School of Medicine, Chief Scientist of the Translational Research Collaborative Innovation Center at the same university’s School of Medicine, and an adjunct professor of the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School.
Prior to returning to China, Dr. Bin-bing Zhou was a Senior Director of Oncology Research Unit-East at Pfizer, mainly responsible for the discovery of anticancer medicine and mechanism of cancers. Leveraging his extensive researches on tumor resistance mechanism and new drugs to overcome the resistance, Dr. Zhou has achieved good results in scientific theories and technological development.